GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of 6 months in and glucagon is still the thing I get wrong — 30 comments in the full submission. View in context.
561
c/survodutide·submitted 1 year ago by u/zeynep_ndiaye

6 months in and glucagon is still the thing I get wrong

Questionbranch of 8 comments

Posting this because I searched for it and got nothing useful. Setup: 10mg, week 13, injection-site soreness present but not ruining anything. I changed exactly one variable — hepatic fat — and tracked it for 7 weeks. Result: a difference, but a small one, and well inside what I would call noise if someone else…

Read the full submission and all 30 comments →

This branch

8 comments, started 1 year ago
u/tomas_lokken14 points·1 year ago

Came off after 55 weeks for financial reasons. Regained about a third over the following year. Back on now at a much lower dose.

replysharereportpermalink
u/incretin_ivypharmacology7 points·1 year ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/mod_cold_roommod · c/coldchain3 points·1 year ago

glucagon injection is a different vector than GLP-1

replysharereportpermalink
load more comments (1) →
u/britt_abubakar11 points·1 year ago

Came off after 55 weeks for financial reasons.

Disagree on that part. 98.1% and 98.3% on the same vial is normal.

replysharereportpermalink
u/zeynep_ndiayeOP7 points·1 year ago

Not to be pedantic but MASH and glucagon are being used interchangeably and they are not interchangeable in real life.

replysharereportpermalink
u/britt_okwuosa5 points·1 year ago·edited

Small correction: the trial was 18 weeks, not 24. Does not change your point but people will quote it.

replysharereportpermalink
u/laila_yilmaz3 points·1 year ago

Which trial arm?

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →